Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes
Portfolio Pulse from Benzinga Newsdesk
Better Therapeutics, Inc. (NASDAQ:BTTX) has announced the commercial launch of AspyreRx, the first cognitive behavioral therapy (CBT) app to receive FDA authorization as a Class II device to treat adults with type 2 diabetes. The app, backed by a randomized controlled trial, demonstrated significant reductions in A1c at 90 and 180 days, improvements in blood pressure, weight, mood, and quality of life, and lower medication utilization and fewer adverse events compared to the control group.
October 16, 2023 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The launch of AspyreRx, a first-of-its-kind FDA-authorized app, could potentially boost Better Therapeutics' market position and revenue. The app's successful trial results further enhance its potential.
The launch of a new, FDA-authorized product typically has a positive impact on a company's stock as it opens up new revenue streams. The successful trial results of AspyreRx further enhance its market potential, which could lead to increased investor confidence in Better Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100